Glancy Donovan Michael 4
4 · COLLEGIUM PHARMACEUTICAL, INC · Filed May 18, 2026
Research Summary
AI-generated summary of this filing
COLL Director Glancy Donovan Michael Receives 17,482 RSUs
What Happened Glancy Donovan Michael, a director of Collegium Pharmaceutical, was awarded 17,482 restricted stock units (RSUs) on 2026-05-14 (reported on Form 4 filed 2026-05-18). The grant is reported as an award (code A) with no purchase price ($0) because RSUs are a form of equity compensation that convert into common shares upon vesting.
Key Details
- Transaction date: 2026-05-14; Form 4 filed: 2026-05-18 (appears timely under the two-business-day rule).
- Award type and size: 17,482 RSUs granted (reported acquisition = 17,482 shares at $0.00).
- Vesting schedule (footnote): 8,741 RSUs vest on the earlier of May 14, 2027 or the Issuer’s 2027 Annual Meeting; the other 8,741 RSUs vest on May 14, 2027 — both subject to continued service.
- Settlement: RSUs will be settled in shares on the vesting dates, or earlier at the director’s election upon end of service, death/disability, or a change in control.
- Shares owned after transaction: not disclosed in the provided filing.
Context RSU grants are standard compensation for directors and are not an open-market purchase or sale. They represent a right to receive common stock in the future (one RSU = one share on settlement). This award does not itself indicate buying or selling pressure; any market impact would occur only when RSUs vest and shares are issued or sold.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-14+17,482→ 17,482 total
Footnotes (1)
- [F1]Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. 8,741 of the RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders; 8,741 of the RSUs vest on May 14, 2027, in each case subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.